Detalles de la búsqueda
1.
For optimal antibody effectiveness, sometimes less is more.
Nature
; 614(7948): 416-418, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36725942
2.
TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice.
Cancer Immunol Immunother
; 64(10): 1229-39, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26091797
3.
Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.
Blood
; 121(2): 251-9, 2013 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-23086756
4.
A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.
Int J Cancer
; 135(4): 820-9, 2014 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24390981
5.
Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity.
Nat Commun
; 15(1): 682, 2024 Jan 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38267413
6.
Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity.
Nat Commun
; 15(1): 683, 2024 Jan 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38267402
7.
Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer.
Int J Cancer
; 132(3): 580-90, 2013 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22733292
8.
Strategies for clinical dose optimization of T cell-engaging therapies in oncology.
MAbs
; 15(1): 2181016, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36823042
9.
Characterization of a novel potency endpoint for the evaluation of immune checkpoint blockade in humanized mice.
Front Immunol
; 14: 1107848, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36936963
10.
Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments.
Front Immunol
; 14: 1258291, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37920465
11.
Small Gene Networks Delineate Immune Cell States and Characterize Immunotherapy Response in Melanoma.
Cancer Immunol Res
; 11(8): 1125-1136, 2023 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37229623
12.
Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma.
J Immunother Cancer
; 11(8)2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37553182
13.
Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.
J Immunol
; 184(4): 1885-96, 2010 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20089697
14.
Deep phenotyping of surface stimulatory and inhibitory co-receptors on cancer-resident T and NK cells reveals cell subsets within the tumor-reactive CTL population that are uniquely defined by NKG2A expression.
SLAS Discov
; 27(2): 95-106, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35058180
15.
Impact of CTLA-4 checkpoint antibodies on ligand binding and Transendocytosis.
Front Immunol
; 13: 871802, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36119113
16.
Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation.
Oncoimmunology
; 11(1): 2117321, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36117525
17.
In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue.
J Exp Med
; 219(6)2022 06 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35472220
18.
A LAT-Based Signaling Complex in the Immunological Synapse as Determined with Live Cell Imaging Is Less Stable in T Cells with Regulatory Capability.
Cells
; 10(2)2021 02 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-33671236
19.
Cyton2: A Model of Immune Cell Population Dynamics That Includes Familial Instructional Inheritance.
Front Bioinform
; 1: 723337, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-36303793
20.
Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control.
Clin Cancer Res
; 27(15): 4353-4366, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34011558